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Abstract 
 
The association between subclinical thyroid dysfunction and cardiovascular outcomes has 
been recently clarified with the publication of three individual participant data (IPD) analyses 
from the Thyroid Studies Collaboration. We identified original cohort studies in a systematic 
review and pooled individual data from over 55’000 participants to get a more precise 
estimate of the risks of cardiovascular outcomes associated with subclinical thyroid 
dysfunction. 
Subclinical hypothyroidism and subclinical hyperthyroidism, defined as normal thyroxine 
levels with increased or decreased thyrotropin (TSH) respectively, are associated with 
increased risk of cardiovascular outcomes compared to euthyroid state, particularly in those 
with a more pronounced thyroid dysfunction. Specifically, subclinical hypothyroidism is 
associated with an increased risk of coronary heart disease (CHD) events, CHD mortality and 
heart failure events in individuals with higher TSH levels, particularly in those with TSH 
levels ≥10.0 mIU/L. Conversely, subclinical hyperthyroidism is associated with an increased 
risk of total mortality, CHD mortality, heart failure and atrial fibrillation, particularly in those 
with suppressed TSH levels <0.10 mIU/L. 
Pending future randomized controlled trials, these observational findings allow identifying 
potential TSH thresholds for thyroid medication initiation based on clinical outcomes, 
although clinical decision based solely on observational data need caution. The impact of 
thyroid replacement among the elderly with subclinical hypothyroidism will be studied in a 
multicenter international randomized controlled trial (Thyroid Hormone Replacement for 
Subclinical Hypothyroidism Trial, TRUST trial). 
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Introduction 
 
In contrast to overt dysfunction, the evidence for treating subclinical thyroid dysfunction is 
still subject to controversy.(1-3) (+ ref Gharib) Current guidelines are based on expert 
consensus, sometimes with diverging conclusions,(ref Gharib) and the debate persists whether 
screening of subclinical thyroid dysfunction should be conducted. The treatment of 
subclinical thyroid dysfunction aims to prevent progression to overt dysfunction and 
cardiovascular complications, but it may also prevent osteoporosis and improve mood, 
muscular and cognitive function.(4) 
The prevalence of subclinical thyroid disorder increases with age (ref NHANES Hollowell), 
as well as heart failure (HF) especially among the elderly.(5) HF remains one of the most 
frequent cause of hospitalizations in persons older than 65 years (ref?). Data on the 
association between subclinical thyroid dysfunction and the risk of coronary heart disease 
(CHD), HF and atrial fibrillation (AF) is conflicting among several large prospective cohorts 
and meta-analyses.(6-8) Furthermore, interpretation of those studies was hampered by several 
methodological issues. (9) 
The publication of three recent pooled individual participant data (IPD) analyses has 
permitted to strengthen the association between subclinical thyroid dysfunction and 
cardiovascular outcomes.(order refs by pub date)(10-12) Subclinical thyroid dysfunction is an 
easy to treat condition that might have a role in the prevention of the occurrence of 
cardiovascular outcomes. However, no randomized controlled trials has reported on the 
potential benefits and harms of the treatment of subclinical thyroid dysfunction. 
In this review, we will describe the association between subclinical hypothyroidism and 
cardiovascular outcomes such as CHD, HF and cardiovascular mortality, and similarly the 
association between subclinical hyperthyroidism and CHD, HF, incident AF and mortality. As 
pathophysiological mechanisms behind subclinical thyroid dysfunction on the cardiovascular 
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system have been extensively described, these will not be the main subject of this review. (13-
17) (I would keep only Biondi 2008: it is the most thorough review: 60 pages!) 
 
The Thyroid Studies Collaboration 
The recent IPD publications were performed within a research network of experts entitled 
"The Thyroid Studies Collaboration".(3 ref) After a systematic review,(6) all available 
published cohorts that assessed prospectively the relation between subclinical thyroid 
dysfunction and cardiovascular outcomes were invited to join the Collaboration and share 
individual data. Data from different cohorts were pooled and summarized as recommended 
using forest plots (Ref 18,19) This process has been repeated for each different cardiovascular 
disease (CVD) outcomes. 
IPD analysis is indeed the best known method to assess the impact of different subgroups on 
the occurrence of different clinical outcomes using standard definition of predictors and 
outcomes. (18, 19)(keep Simmonds 2005) Pooling different dataset across several cohorts 
increases power to detect epidemiological associations that might be undetectable in one 
cohort or conflicting results between cohorts. IPD analysis is considered the optimal design to 
summarize evidence across studies. It permits to reduce potential bias from study level meta-
analyses (ecological fallacy), to adjust with same confounders and to perform time-to-event 
analyses.(19-21) Data from different cohorts were pooled and summarized as recommended 
using forest plots for each outcome. (22, 23) 
The Thyroid Studies Collaboration is open to collaborate with authors of other published 
cohorts in the future. Such a large and international collaboration is an opportunity to perform 
research on the association between subclinical thyroid disorder and cardiovascular diseases. 
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Subclinical Hypothyroidism 
Definition and Epidemiology 
Subclinical hypothyroidism is defined as a Thyroid-Stimulating Hormone (TSH, or 
thyrotropin) level above the upper limit of the reference range with normal free thyroxine 
(FT4) concentration. Guidelines recommend to reassess serum TSH level within 3 to 6 
months to confirm persistent TSH abnormalities. (ref 4) For the IPD analyses, we used a 
uniform TSH cutoff level (>4.5 mIU/L), based on an expert consensus meeting of our Thyroid 
Studies Collaboration (International Thyroid Conference, Paris, 2010), expert reviews (ref 
Surks, Helfand) and previous large cohorts (ref Cappola, Walsh, Boekholdt). 
Subclinical thyroid dysfunction is more common than overt dysfunction, with a prevalence for 
subclinical hypothyroidism reaching up to 10% among the elderly.(15) Subclinical 
hypothyroidism is a transitory laboratory finding in a fair amount of cases, partially due to 
laboratory imprecision, especially when TSH levels are ≤10.0 mIU/L. Up to 60% of persons 
with subclinical hypothyroidism will spontaneously revert to a euthyroid state, while 1-5% 
per year will progress to an overt thyroid dysfunction.(check ref Somwaru, JCEM,2012) The 
presence of antithyroid antibodies, such as anti-thyroid peroxidase antibodies (TPOAb), has 
been associated with an increased risk of progression to overt thyroid dysfunction,(ref 
Somwaru) but their use in clinical decisions is still subject to controversy.(24)  
Subclinical hypothyroidism and cardiovascular system 
Subclinical hypothyroidism has been associated with cardiac abnormalities, such as left 
ventricular dysfunction and depressed systolic function at rest and during effort. This 
condition has also been associated with vascular abnormalities, such as increased vascular 
resistance, arterial stiffness, changes in endothelial function, and atherosclerosis.(25) Higher 
TSH levels have been correlated with decreased left ventricular stroke volume, decreased in 
cardiac index, and increased systemic vascular resistance.(26) Restoration of a euthyroid state 
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in patients with subclinical hypothyroidism was found to normalize different cardiac and 
vascular structural parameters.(14, 27-29) 
Subclinical hypothyroidism and total and CHD mortality 
The IPD analysis (ref Rodondi, JAMA, 2010) for the association between subclinical 
hypothyroidism and total mortality pooled 51'837 euthyroid and 3450 participants with 
subclinical hypothyroidism from 11 prospective cohorts in the Unites States, Australia, Asia, 
South America and Europe (Table 1). (30-40) Compared to euthyroidism, the age and gender-
adjusted hazard ratio (HR) for total mortality with subclinical hypothyroidism was 1.09 (95% 
confidence interval [CI], 0.96-1.24). In contrast to CHD events and mortality, the risk of total 
mortality was not significantly increased with higher TSH levels. (Figure 1) 
The IPD analysis (11) for the association between subclinical hypothyroidism and CHD 
mortality pooled 10 studies with 50'953 euthyroid and 3348 participants with subclinical 
hypothyroidism (Table 1). (30-33, 35-39, 41) Compared to euthyroidism, the age and gender-
adjusted HR for CHD mortality with subclinical hypothyroidism was 1.14 (95% CI, 0.99-
1.32) and increased significantly with higher levels of TSH (p for trend 0.005), particularly in 
those with a TSH between 7.0-9.9 mIU/L (HR 1.42, 95% CI 1.03-1.95) and a TSH ≥10.0 
mIU/L (HR 1.58, 95% CI 1.10-2.27) (Figure 2).  
Subclinical hypothyroidism and CHD events 
The IPD analysis (11) for the association between subclinical hypothyroidism and CHD 
events included 23'957 euthyroid participants and 2020 with subclinical hypothyroidism from 
7 prospective studies in United Stated, Australia and Europe (Table 2). (30, 31, 33, 35-38) 
Compared to euthyroidism, the age and gender-adjusted HR for CHD events with subclinical 
hypothyroidism was 1.18 (95% CI 0.99-1.42). The risk of CHD events increased significantly 
with higher levels of TSH (p for trend <0.001), particularly in those with TSH levels ≥10.0 
mIU/L (HR 1.89, 95% CI 1.28-2.80) (Figure 3). Minimal TSH disturbances were not 
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associated with CHD events: HR was 1.00 (95% CI 0.86-1.18) for a TSH between 4.5 and 6.9 
mIU/L.  
Subclinical hypothyroidism and HF events 
 
The IPD analysis of 25'390 participants from 6 prospective cohorts in the Unites States and 
Europe (30, 31, 33, 35, 42, 43) showed that the risk of HF events was increased with higher 
levels of TSH, particularly in those with TSH ≥10.0 mIU/L (Table 2). (12) Considering the 
total population of participants with subclinical thyroid dysfunction (TSH 4.5-19.9 mIU/L), 
the risk was not significantly increased, because the majority of participants had a mild TSH 
disturbance (TSH 4.5-6.9 mIU/L) (Figure 4). These results confirmed that subclinical thyroid 
dysfunction is a heterogeneous identity with varying risk of HF events according to TSH 
levels as observed with CHD events and CHD mortality. As previously described, ventricular 
diastolic dysfunction has been associated with subclinical hypothyroidism and might precede 
the clinical development of HF observed across prospective cohorts. (44) In addition to the 
cardiac structure abnormalities associated with higher TSH levels, the increased risk of CHD 
events might also contribute to the development of HF, as CHD is a common cause of HF. 
(45, 46) However, the exclusion of preexisting CVD in sensitivity analyses did not change the 
findings. (12) 
 
Subclinical Hyperthyroidism 
Definition and Epidemiology 
Subclinical hyperthyroidism is defined as a serum TSH concentration below the lower limit of 
the reference range (<0.45 mIU/L) with normal serum FT4 and free tri-iodothyronine (FT3). 
(1, 2, 24) For the IPD analyses, we again used a uniform TSH cutoff level (<0.45 mIU/L), 
based on an expert consensus meeting of our Thyroid Studies Collaboration (International 
Thyroid Conference, Paris, 2010), expert reviews (ref Surks, Helfand) and previous large 
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cohorts (ref Cappola, Walsh, Boekholdt). In order to study the risks associated with 
endogenous subclinical hyperthyroidism and the iatrogenic counterpart, we excluded 
participants on thyroid medication at baseline. 
The prevalence of subclinical hyperthyroidism is approximately 1%, but varies according to 
age, gender and iodine intake. (15) Subclinical hyperthyroidism might be a transitory 
abnormality that occurs when TSH levels are low with normal FT3 and FT4. In fact, up to 
50% of persons with subclinical hyperthyroidism will spontaneously revert to a euthyroid 
state within several months, whereas 1-15% per year will progress to an overt dysfunction. (4) 
Subclinical hyperthyroidism and cardiovascular system 
FT3 has an important role in the regulation of cardiovascular system. High levels of FT3 are 
correlated with higher cardiac rate, increased frequency of atrial and ventricular premature 
beats, increased left ventricular mass and some systolic and diastolic abnormalities. (47) Thus 
abnormalities in addition to vascular changes, such as increased carotid intima-media 
thickness or carotid artery plaque might lead to an increased risk of mortality and 
cardiovascular disorders associated with subclinical hyperthyroidism.(8, 15, 47-49) 
Subclinical hyperthyroidism and total and CHD mortality 
 
The IPD analysis (ref) for the association between subclinical hyperthyroidism and total 
mortality combined 50'486 euthyroid and 2188 participants with subclinical hyperthyroidism 
from 10 prospective cohorts in the Unites States, Australia, South America and Europe 
(Table 1). Compared to euthyroidism, the age and gender-adjusted HR for total mortality with 
subclinical hyperthyroidism was 1.24 (95 % CI 1.06-1.46) (Figure 1). In contrast to CHD 
mortality, the risk of total mortality was not significantly increased with lower TSH levels, 
possibly due to the low number of events in this category. 
The IPD analysis (ref) for the association between subclinical hyperthyroidism and CHD 
mortality pooled 50'456 euthyroid and 2177 participants with subclinical hypothyroidism 
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from the same 10 cohorts (Table 2). Compared to euthyroidism, the age and gender-adjusted 
HR for CHD mortality with subclinical hyperthyroidism was 1.29 (95% CI 1.02-1.62). The 
risk increased significantly with lower levels of TSH (p for trend 0.02), particularly in those 
with a TSH <0.10 mIU/L (HR 1.84, 95% CI 1.12-3.00) (Figure 2).  
Subclinical hyperthyroidism and CHD events and incident AF 
 
The IPD analysis (ref) for the association between subclinical hyperthyroidism and CHD 
events included 21'714 euthyroid and 723 participants with subclinical hyperthyroidism from 
6 prospective cohorts in the United States, Australia and Europe (Table 2). Compared to 
euthyroidism, the age and gender-adjusted HR for CHD events with subclinical 
hyperthyroidism was 1.21 (95% CI 0.99-1.46). The risk of CHD events was not significantly 
increased with lower TSH levels (Figure 3). 
The risk of incident AF was also increased with subclinical hyperthyroidism: HR was 1.63 
(95% CI 1.10-2.41) for TSH 0.10-0.44 mIU/L and 2.54 (95% CI 1.08-5.99) for TSH < 0.10 
mIU/L (p for trend 0.02). The increased risk of AF events with subclinical hyperthyroidism 
were also reported in previous longitudinal studies.(30, 50-52) 
Subclinical hyperthyroidism and HF events  
 The IPD analysis (ref) of 23'322 participants from 6 prospective cohorts in the United States 
and Europe (16, 18, 20, 28, 29) showed that the risk of HF increased with lower TSH levels, 
particularly in those with TSH levels <0.10 mIU/L (Figure 4). In fact, there was a significant 
parabolic association between TSH levels and the risk of HF events. The U-shaped curve of 
this association showed increased risks of HF for extreme TSH values, similarly to the risk of 
CHD mortality (Figure 2). Considering the total population with subclinical hyperthyroidism 
(<0.45 mIU/L), and as the majority of participants had slight disturbances of TSH levels 
(0.10-0.44 mIU/L), the risk of HF events was not significantly increased (HR 1.46, 95% CI 
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0.94-2.27) (Table 2). The observed association persisted after excluding preexisting HF or 
preexisting AF, which are common causes of HF hospitalization.  
 
Conclusion 
 
Subclinical hypothyroidism is associated with an increased risk of CHD events, CHD 
mortality and HF events, but not of total mortality. The risk is increased with higher 
concentrations of TSH, particularly in those with TSH ≥10.0 mIU/L. Conversely, mild TSH 
elevations are not significantly associated with increased risks of cardiovascular outcomes. 
Endogenous subclinical hyperthyroidism is associated with an increased risk of total 
mortality, CHD mortality, CHD, AF and HF events. The risks of CHD mortality, AF and HF 
events are more pronounced with lower TSH levels, particularly in those with suppressed 
TSH levels <0.10 mIU/L. However, mild decrease of TSH levels are not associated with an 
increased risk of CHD events and total mortality. The risks were similar after further 
adjustment for cardiovascular risks factors. The stratified analyses according to gender, age 
and race did not significantly change the findings. Sensitivity analyses excluding those with 
thyroid medication or previous CVD did not alter results. 
The three reported IPD analyses confirmed that subclinical thyroid dysfunction is a 
heterogeneous entity with varying risk of CVD and mortality according to TSH levels. The 
risk of different CVD is more pronounced with in both severe subclinical hypothyroidism and 
hyperthyroidism. In fact, these findings are compatible with a continuum between subclinical 
and overt thyroid dysfunction according to TSH levels. (16, 17) Individuals with mild TSH 
disturbances (4.5-6.9 mIU/L) are not at increased risk of cardiovascular outcomes based on 
the reviewed observational data, although a large proportion of this population is treated in 
clinical practice.(11, 53) 
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Clinical implications 
 
The findings from three IPD analyses have led to a better interpretation of TSH levels in the 
prevention and investigation of CHD, AF and HF events. While awaiting results from RCTs, 
these results may prove useful to define a TSH threshold for thyroid medication initiation 
based on clinical outcomes.,(54) However, as observational studies are subject to several 
limitations, clinical decision based only on these observational data should be made with great 
caution. The American College of Cardiology and the American Heart Association Guidelines 
for the diagnosis and management of HF in adults recommend the assessment of thyroid 
function to investigate conditions that might exacerbate HF, such as hypothyroidism or 
hyperthyroidism.(55) Studies on the addition of anti-thyroid antibodies in the prediction of 
cardiovascular events might be helpful to inform clinical decision making for patients with 
subclinical hypothyroidism. Recent guidelines recommend that "treatment of subclinical 
hyperthyroidism should be strongly considered in all individuals ≥65 years of age" with TSH 
level <0.10 mIU/L and "treatment of subclinical hyperthyroidism should be considered in 
individuals ≥ 65 years of age" with low TSH levels ≥0.10 mIU/L (ref Bahn). The recent 
findings in these IPD analyses are consistent with the current guidelines. In particular, the 
early recognition and treatment of subclinical hyperthyrodism might prevent the development 
of cardiac related complications, such as AF, HF and mortality.  
Given the high prevalence of subclinical hypothyroidism and CVD among the elderly, a large 
randomized controlled trial has been started in Europe. The Thyroid Hormone Replacement 
for Subclinical Hypothyroidism trial (TRUST trial) will help to clarify the potential benefit of 
thyroxine replacement on the cardiovascular outcomes.  
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Table 1 The risk of Total and CHD mortality according to subclinical thyroid dysfunction compared to euthyroidism 
Study Description of study sample Total Mortality CHD Mortality 
    Euthyroidism Subclinical 
hypothyroidism 
Subclinical 
hyperthyroidism 
Euthyroidism Subclinical 
hypothyroidism 
Subclinical 
hyperthyroidism 
United States  
 HR (95% CI) HR (95% CI)  HR (95% CI) HR (95% CI) 
Cardiovascular Health Study 
(30) 
Community-dwelling adults with Medicare eligibility 
in 4 US communities 
1 (Ref) 1.07 (0.95-1.21) 1.04 (0.70-1.53) 1 (Ref) 1.09 (0.85-1.40) 1.35 (0.67-2.72) 
Health, Aging and Body 
Composition Study (31) 
Community-dwelling adults with Medicare eligibility 
in 2 US communities 
1 (Ref) 0.89 (0.72-1.11) 1.25 (0.73-2.12) 1 (Ref) 0.85 (0.53-1.37) 0.76 (0.19-3.09) 
Europe  
 
   
  
Birmingham Study(32) Community-dwelling adults aged ≥60 years from 
primary care practice in Birmingham, England 
1 (Ref) 0.92 (0.64-1.33) 1.39 (0.95-2.02) 1 (Ref) 1.21 (0.64-2.29) 1.50 (0.73-3.09) 
EPIC-Norfolk Study (33) Adults living in Norfolk, England 1 (Ref) 0.97 (0.80-1.18) 1.05 (0.82-1.36) 1 (Ref) 1.19 (0.83-1.72) 1.24 (0.77-2.02) 
HUNT Study (41) Adults living in Nord-Trøndelag County, Norway 1 (Ref) 0.99 (0.82-1.19) 1.52 (1.18-1.97) 1 (Ref) 1.09 (0.72-1.65) 0.95 (0.42-2.13) 
Leiden 85+ Study (35) All adults aged 85 years living in Leiden, the 
Netherlands 
1 (Ref) 0.85 (0.57-1.27) 1.49 (0.95-2.32) 1 (Ref) 0.87 (0.27-2.82) 0.65 (0.09-4.74) 
Pisa cohort (36) Patients admitted to cardiology department in Pisa, 
Italy f 
1 (Ref) 2.13 (1.52-3.00) 1.12 (0.71-1.74) 1 (Ref) 1.91 (1.08-3.36) 1.93 (1.10-3.40) 
Whickham Survey (37) Adults living in and near Newcastle upon Tyne, 
England 
1 (Ref) 0.98 (0.73-1.31) NA 1 (Ref) 1.08 (0.64-1.81) NA 
SHIP (ref) Adults living in Western Pomerania, Germany 1 (Ref) NA 0.99 (0.81-1.21) 1 (Ref) NA 1.08 (0.64-1.84) 
PROSPER study (ref)  Older community-dwelling adults at high 
cardiovascular risk in the Netherland, Ireland. and 
Scotland 
NA NA NA NA NA NA 
Bari cohort (ref) Outpatients with HF followed up by Cardiology 
Department in Bari, Italy 
NA NA NA NA NA NA 
Australia 
  
 
   
  
Busselton Health Study (ref) Adults living in Busselton, Western Australia 1 (Ref) 1.44 (1.02-2.03) 1.03 (0.57-1.88) 1 (Ref) 1.67 (0.94-2.97) 0.91 (0.29-2.85) 
Southern America 
  
 
   
  
Brazilian Thyroid Study (ref) Adults of Japanese descent living in São Paulo, Brazil 1 (Ref) 1.96 (1.07-3.61) 2.73 (1.53-4.88) 1 (Ref)  2.35 (0.50-11.14) 
Asia        
Nagasaki Adult Health Study 
(ref) 
Atomic bomb survivors in Nagasaki, Japan 1 (Ref) 1.04 (0.83-1.31) NA 1 (Ref) 0.67 (0.23-1.91) NA 
Overall  1 (Ref) 1.09 (0.96-1.24) 1.24 (1.06-1.46) 1 (Ref) 1.14 (0.99-1.32) 1.29 (1.02-1.62) 
Abbreviations: NA, not available in the previous individual participant data analyses; CHD, coronary heart disease; HF, heart failure; HR, hazard ratio; CI, confidence intervals   
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Table 2 The risk of CHD and HF events according to subclinical thyroid dysfunction compared to euthyroidism 
Study Description of study sample CHD Events HF Events 
    Euthyroidism Subclinical 
hypothyroidism 
Subclinical 
hyperthyroidism 
Euthyroidism Subclinical 
hypothyroidism 
Subclinical 
hyperthyroidism 
United States  
 HR (95% CI) HR (95% CI)  HR (95% CI) HR (95% CI) 
Cardiovascular Health Study 
(ref) 
Community-dwelling adults with Medicare eligibility 
in 4 US communities 
1 (Ref) 1.00 (0.85-1.17) 1.12 (0.69-1.81) 1 (Ref) 0.91 (0.75-1.10) 1.12 (0.64-1.93) 
Health, Aging and Body 
Composition Study  (ref) 
Community-dwelling adults with Medicare eligibility 
in 2 US communities 
1 (Ref) 0.89 (0.68-1.16) 1.59 (0.90-2.83) 1 (Ref) 1.02 (0.74-1.39) 0.84 (0.43-1.64) 
Europe        Birmingham Study (ref) Community-dwelling adults aged ≥60 years from 
primary care practice in Birmingham, England 
NA NA NA NA NA NA 
EPIC-Norfolk Study (ref) Adults living in Norfolk, England 1 (Ref) 1.09 (0.89-1.33) 1.12 (0.85-1.49) 1 (Ref) 1.39 (0.99-1.95) 0.94 (0.53-1.66) 
HUNT Study (ref) Adults living in Nord-Trøndelag County, Norway NA NA NA NA NA NA 
Leiden 85+ Study (ref) All adults aged 85 years living in Leiden, the 
Netherlands 
1 (Ref) 1.29 (0.59-2.80) 1.37 (0.50-3.74) 1 (Ref) 1.00 (0.44-2.31) 2.13 (0.98-4.63) 
Pisa cohort (ref) Patients admitted to cardiology department in Pisa, 
Italy f 
1 (Ref) 1.72 (1.07-2.74) 1.33 (0.79-2.22) NA NA NA 
Whickham Survey (ref) Adults living in and near Newcastle upon Tyne, 
England 
1 (Ref) 1.32 (0.89-1.96) NA NA NA NA 
SHIP (ref) Adults living in Western Pomerania, Germany NA NA NA NA NA NA 
PROSPER study (ref) Older community-dwelling adults at high 
cardiovascular risk in the Netherland, Ireland. and 
Scotland 
NA NA NA 1 (Ref) 1.13 (0.70-1.83)  2.81 (1.60-4.94) 
Bari cohort (ref) Outpatients with HF followed up by Cardiology 
Department in Bari, Italy 
NA NA NA 1 (Ref) 3.12 (1.86-5.21) 2.50 (0.78-8.03) 
Australia        Busselton Health Study (ref) Adults living in Busselton, Western Australia 1 (Ref) 1.78 (1.22-2.58) 1.15 (0.59-2.24) NA NA NA 
Southern America        Brazilian Thyroid Study (ref) Adults of Japanese descent living in São Paulo, Brazil NA NA NA NA NA NA 
Asia        
Nagasaki Adult Health Study 
(ref) 
Atomic bomb survivors in Nagasaki, Japan NA NA NA NA NA NA 
Overall  1 (Ref) 1.18 (0.99-1.42) 1.21 (0.99-1.46) 1 (Ref) 1.26 (0.91-1.74) 1.46 (0.94-2.27) 
Abbreviations: NA, not available in the previous individual participant data analyses; CHD, coronary heart disease; HF, heart failure; HR, hazard ratio; CI, confidence intervals   
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